萬方發展(000638.SZ):萬方百奧擬收購亞東生物(安國)不低於15%的股權
格隆匯 3 月 11日丨萬方發展(000638.SZ)公佈,為加快公司進入疫苗行業,公司控股子公司吉林萬方百奧生物科技有限公司(“萬方百奧”)於2021年3月9日與北京富亞東投資管理有限公司(“富亞東”)、北京亞東生物製藥(安國)有限公司(“亞東生物(安國)”或“標的公司”)簽訂了《股權轉讓框架協議》,根據股權轉讓框架協議約定,萬方百奧擬收購富亞東持有的亞東生物(安國)不低於15%的股權,首付款為人民幣3000萬元。
亞東生物(安國)目前擁有重組乙型肝炎疫苗(CHO細胞)藥品文號(兩個規格:國藥準字S19990072 (10μg/0.5ml)、國藥準字S20010009 (20μg/1.0ml)),分別用於新生兒(一類)和母嬰阻斷(二類)的乙肝免疫治療,目前兩個文號正在進行現場認證前的準備工作。
此次收購的標的公司亞東生物(安國)具備疫苗生產資質,並擁有重組乙型肝炎疫苗(CHO細胞)藥品文號(兩個規格:國藥準字S19990072 (10μg/0.5ml)、國藥準字S20010009 (20μg/1.0ml)),公司將主導兩個乙肝疫苗儘早批簽發上市,並最終取得亞東生物(安國)的控制權。收購亞東生物(安國)是公司向疫苗業務進軍的關鍵里程碑節點,公司已與多家科研機構開展生物製品方面的合作,急需疫苗生產資質用於研發成果的落地轉化,對公司在生物科技領域的發展有着積極的影響,符合全體股東的利益和公司長遠發展戰略。公司預計該項合作短期內不會對公司的財務狀況造成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.